血浆N-聚糖作为心脏代谢风险的新兴生物标志物:EPIC-波茨坦队列的前瞻性研究
基于EPIC-波茨坦前瞻性队列(n=27,548)构建病例队列,纳入随机亚样本2,500人及全部医师确认的2型糖尿病(n=820,中位随访6.5年)和心血管疾病(n=508,中位随访8.2年)新发病例,用色谱法检测基线血浆39种N-聚糖组的相对丰度,通过交叉验证机器学习等构建加权预测评分。N-聚糖的2型糖尿病评分内部验证加权C指数0.83(95%CI 0.78-0.88)并在FINRISK外验证;心血管疾病预测男性加权C指数0.66(95%CI 0.60-0.72)、女性0.64(95%CI 0.55-0.73);所选N-聚糖可提高现有风险评分的准确性。
要点
- N-聚糖糖尿病评分内部验证加权C指数0.83(95%CI 0.78-0.88),并在FINRISK外验证。
- 心血管疾病预测男性加权C指数0.66(95%CI 0.60-0.72),女性0.64(95%CI 0.55-0.73)。
- 所选N-聚糖可提高现有2型糖尿病和心血管疾病风险预测评分的准确性。
核心结论
- 所选N-聚糖在现有风险标志物之外改善2型糖尿病和心血管疾病预测。
- 血浆蛋白N-聚糖谱可能有助于心脏代谢疾病精准靶向一级预防中的风险分层。
研究设计与样本
- 基于EPIC-波茨坦前瞻性队列(n=27,548)构建病例队列,含随机亚样本2,500人及全部医师确认的2型糖尿病(n=820,中位随访6.5年)和心血管疾病(n=508,中位随访8.2年)新发病例。
- 用色谱法检测基线血浆样本中39种N-聚糖组的相对丰度。
- 基于交叉验证机器学习、非线性模型构建和加权预测评分,分别筛选2型糖尿病和心血管疾病的预测性N-聚糖;心血管疾病流程在男性和女性中分别应用。
主要发现
- 基于N-聚糖的2型糖尿病评分在内部验证队列中强预测糖尿病风险,加权C指数0.83(95%CI 0.78-0.88),并在FINRISK队列外验证。
- N-聚糖对心血管疾病发病具有中等预测能力,男性加权C指数0.66(95%CI 0.60-0.72),女性0.64(95%CI 0.55-0.73)。
- 所选N-聚糖信息提高了已建立且临床应用的2型糖尿病和心血管疾病风险预测评分的准确性。
关键数值与推荐
- 2型糖尿病评分内部验证加权C指数0.83(95%CI 0.78-0.88)。
- 心血管疾病预测男性加权C指数0.66(95%CI 0.60-0.72),女性0.64(95%CI 0.55-0.73)。
临床怎么用
- 血浆蛋白N-聚糖谱可能有助于心脏代谢疾病精准靶向一级预防中的风险分层。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Plasma protein N-glycan profiling integrates information on enzymatic protein glycosylation, which is a highly controlled ubiquitous posttranslational modification. Here we investigate the ability of the plasma N-glycome to predict incidence of type 2 diabetes and cardiovascular diseases (CVDs; i.e., myocardial infarction and stroke). RESEARCH DESIGN AND METHODS: Based on the prospective European Prospective Investigation of Cancer (EPIC)-Potsdam cohort (n = 27,548), we constructed case-cohorts including a random subsample of 2,500 participants and all physician-verified incident cases of type 2 diabetes (n = 820; median follow-up time 6.5 years) and CVD (n = 508; median follow-up time 8.2 years). Information on the relative abundance of 39 N-glycan groups in baseline plasma samples was generated by chromatographic profiling. We selected predictive N-glycans for type 2 diabetes and CVD separately, based on cross-validated machine learning, nonlinear model building, and construction of weighted prediction scores. This workflow for CVD was applied separately in men and women. RESULTS: The N-glycan-based type 2 diabetes score was strongly predictive for diabetes risk in an internal validation cohort (weighted C-index 0.83, 95% CI 0.78-0.88), and this finding was externally validated in the Finland Cardiovascular Risk Study (FINRISK) cohort. N-glycans were moderately predictive for CVD incidence (weighted C-indices 0.66, 95% CI 0.60-0.72, for men; 0.64, 95% CI 0.55-0.73, for women). Information on the selected N-glycans improved the accuracy of established and clinically applied risk prediction scores for type 2 diabetes and CVD. CONCLUSIONS: Selected N-glycans improve type 2 diabetes and CVD prediction beyond established risk markers. Plasma protein N-glycan profiling may thus be useful for risk stratification in the context of precisely targeted primary prevention of cardiometabolic diseases.
引用
- Wittenbecher C, Štambuk T, Kuxhaus O, et al. Plasma N-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study. Diabetes Care. 2020. PMID: 31915204. doi:10.2337/dc19-1507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。